Spexis AG
SIX:SPEX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Spexis AG
SIX:SPEX
|
CH |
|
Thungela Resources Ltd
OTC:TNGRF
|
ZA |
|
Millennium Pharmacon International Tbk PT
IDX:SDPC
|
ID |
|
S
|
Srithai Superware PCL
SET:SITHAI
|
TH |
|
S
|
Shenzhen FRD Science & Technology Co Ltd
SZSE:300602
|
CN |
|
Preformed Line Products Co
NASDAQ:PLPC
|
US |
|
T
|
Tin Nghia Industrial Park Development JSC
VN:TIP
|
VN |
|
Civista Bancshares Inc
NASDAQ:CIVB
|
US |
|
COSCO SHIPPING Development Co Ltd
SSE:601866
|
CN |
|
U
|
Ugar Sugar Works Ltd
NSE:UGARSUGAR
|
IN |
|
China Merchants Bank Co Ltd
SSE:600036
|
CN |
|
Brilliance Technology Co Ltd
SZSE:300542
|
CN |
Spexis AG
Spexis Ltd. is clinical stage biopharmaceutical company, which engages in the research and development of macrocycle drugs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2018-05-15. The firm focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The firm's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
Spexis Ltd. is clinical stage biopharmaceutical company, which engages in the research and development of macrocycle drugs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2018-05-15. The firm focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The firm's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
